response rate and survival outcomes of patients with stage IV melanoma treated with pembrolizumab in our center. Methods: Patients with pathologically confirmed metastatic melanoma referred to our center from…
various entities not limited to non-small cell lung cancer and malignant melanoma. Pembrolizumab, an anti-PD-1 antibody, has been proven to have strong anti-tumor activity ... unique case of advanced high grade…
during bronchoscopy, and expression of programmed death-ligand 1 was 95%, so chemotherapy with pembrolizumab monotherapy was started. After pembrolizumab administration, serum eosinophil count increased, and systemic…
treat a variety of cancers by enhancing the immune response against cancer cells. Pembrolizumab is a humanized antibody which prevents tumor cells from deactivating host T-cells. Like most forms ... origin due to the…
Pembrolizumab, an anti-programmed death 1 (PD-1) inhibitor is now the focus of cancer research for its favorable clinical response to microsatellite instability (MSI)-high metastatic colorectal cancer ... partial or…
reports of Non-Small Cell Lung Cancer (NSCLC) cases where a single cycle of pembrolizumab monotherapy led to near-complete tumor resolution without any adverse events. Case Presentation ... high Programmed Cell Death…
Pembrolizumab has been approved by the Food and Drug Administration (FDA) to treat multiple cancers one of which is triple-negative breast cancer positive for Programmed Cell Death Ligand ... protein. Multiple…
Pembrolizumab is a humanized monoclonal antibody targeting the anti-Programmed Cell Death 1 (PD-1) receptor expressed on the surface of cytotoxic T lymphocytes. Currently the introduction of immunotherapy ... study. We…
Purpose: To report a case of pembrolizumab-associated idiopathic orbital inflammatory syndrome (IOIS). Observations: A 57 year-old female with a history of metastatic non-small cell lung cancer treated ... with…
these medications can trigger immune-related adverse reactions. Documented immune-related adverse reactions of pembrolizumab include pneumonitis, immune-mediated colitis, hepatitis, endocrinopathies, and nephritis. The…
KEYNOTE-A18 trial is a Phase 3, randomized, non-inferiority study assessing subcutaneous (SC) pembrolizumab (MK- 3475A with hyaluronidase) versus intravenous (IV) pembrolizumab for advanced melanoma, NSCLC, RCC, HNSCC…
Pembrolizumab is a Programmed Cell Death protein-1 (PD-1) inhibitor which leads to increased T-cell activity which in turn increases anti-tumor immune response. Although immune-related Adverse ... current literature…
Pembrolizumab is an Immune Checkpoint Inhibitor (ICI) that exerts anti-tumor activity by inhibiting the interaction of programmed cell death protein 1 with its ligand (PD-L1) on activated lymphocytes.Immune ... with…
year-old man with metastatic melanoma presenting with interstitial pneumonitis following initiation of pembrolizumab, in the setting of occult sarcoidosis. There have been no previous reports on pembrolizumab inducing
four months, easy fatigability and breast pain while showering. He was started on pembrolizumab immunotherapy about 9 months before presentation which he tolerated well. Subsequent endocrine work ups revealed features
ELISA for an antigen detected by a specific monoclonal antibody, named UNIVmAb and with pembrolizumAb for comparison in all human cancers of different grades. This first method is based ... classification along with…
localized radiotherapy, all of which proved ineffective in reducing disease burden. Checkpoint inhibitor pembrolizumab (Keytruda®) was eventually administered. While treatment was effective in decreasing disease burden…
LAPC. The treatment involves a nonconcurrent combination of CHT, RT, IRE, and IO with pembrolizumab. The study assesses the safety, tolerability, and preliminary efficacy of this combined sequential therapy. Biopsies
autopsy finding from a 70-year-old white male with severe myocarditis induced by pembrolizumab administered during the treatment for high grade urothelial carcinoma. He initially presented with left